Page 2 - Motion To Amend Pilot Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Motion to amend pilot program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Motion To Amend Pilot Program Today - Breaking & Trending Today

Discussing AIA Patent Reform Over the Years

Discussing AIA Patent Reform Over the Years
natlawreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from natlawreview.com Daily Mail and Mail on Sunday newspapers.

United States , Supreme Court , Precedential Opinion Panel , Patent Office Administrative Judges Apjs , Motion To Amend Pilot Program , America Invents Act , Patent Office , Administrative Patent Judges , Patent Appeals , Patent Trial , Appeal Board , Humble Editor , President Obama , United States Code , Federal Circuit , Trial Practice Guide , Amend Pilot Program ,

No Unpatentability in a Successful Motion to Amend


No Unpatentability in a Successful Motion to Amend
Tuesday, February 23, 2021
Mylan Labs. Ltd. v. Aventis Pharma S.A., IPR2016-00712, Paper 112 (P.T.A.B. Oct. 22, 2019),
 aff’d without opinion (Fed. Cir. Jan. 15, 2021), the Patent Trial and Appeal Board (“PTAB”) granted Patent Owner’s motion to amend, finding that Petitioner had not shown the proposed substitute claims to be unpatentable.
Background
The drug at issue was JEVTANA
® (cabazitaxel), which is indicated for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. Mylan challenged claims 1-5 and 7-30 of Orange Book-listed U.S. Pat. No. 8,927,592 (“the ’592 patent”) as unpatentable under 35 U.S.C. § 103(a). The ’592 patent, along with two continuation patents that issued from it, moved the patent expiration date for JEVTANA ....

Mayo Alice , Vanda Pharms , Aventis Pharma , Aqua Products Inc , Motion To Amend Pilot Program , Patent Trial , Appeal Board , Patent Owner , Orange Book Listed , Orange Book , Contingent Motion , Final Written Decision , Federal Circuit , Aventi Motion , Sanofi Mature , Aqua Products , Anticipation Based , Ward Pharms , Patent Owners , Appeal Board Motion , Amend Study , Amend Pilot Program , Mylan Labs Ltdv Aventis Pharma , மயோ ஆலிஸ் , வந்தா ஃபார்ம்ஸ் , அவென்ட்டிஸ் பார்மா ,